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Background: HIV / AIDS (Acquired Immune Deficiency Syndrome) is still a health problem in 
the world including in Indonesia. Approximately 36.7 people are infected with HIV in the world 
and in Indonesia until March 2017 recorded 242,699 cases. The recorded amount does not reflect 
the real number in the community because HIV infection often does not show specific symptoms 
before entering the stage of AIDS. This study aimed to examine the application of the health belief 
model on adherence to antiretroviral therapy among HIV/ AIDS patients in Surakarta, Central 
Java. 
Subject and  Method: This was a cross sectional study conducted at Dr. Moewardi Hospital, 
Surakarta, Central Java, on February 2018. A total sample of 284 HIV/AIDS patients was selected 
for this study by exhaustive sampling. The dependent variable was ARV Adherence. The 
independent variables were perceived susceptibility, perceived severity, perceived benefits, 
perceived barriers, cues to action, and self-efficacy. The data were collected using a questionnaire 
and analyzed by a path analysis. 
Results: Adherence directly increased with self-efficacy (b= 2.10; 95% CI = 0.85 to 3.34; p= 
0.001), perceived benefit (b= 2.08; 95% CI= 1.15 to 3.00; p <0.001), and cue to action (b= 3.61; 
95% CI= 0.86  to 6.36; p= 0.010) but decreased with higher perceived barrier (b= 2.08; 95% CI= 
1.15 to 3.00; p<0.001). Adherence indirectly decreased with higher perceived severity and 
perceived susceptibility. 
Conclusion: Self-efficacy, perceived benefit, perceived barrier,  and cue to action directly affect the 
adherence to antiretroviral therapy. Perceived severity and perceived susceptibility indirectly affect the 
adherence to antiretroviral therapy.  
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BACKGROUND 
HIV/ AIDS (Acquired Immune Deficiency 
Syndrome) is still a health problem in the 
world including Indonesia (Ministry of 
Health, 2017; WHO, 2017). Approximately 
36.7 people were infected with HIV in the 
world (WHO, 2017) and in Indonesia until 
March 2017 recorded 242,699 cases 
(Ministry of Health, 2017). The recorded 
amount does not reflect the real number in 
the community because HIV infection often 
does not show specific symptoms before 
entering the stage of AIDS (UNAIDS, 2017). 
The use of HAART (Highly Active 
Antiretroviral Therapy) in the treatment of 
HIV/ AIDS infection decreased mortality 
and morbidity due to HIV/ AIDS infection 
(Becerra et al., 2016; Yoshimura, 2017). 
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Unfortunately, such antiretroviral therapy 
should last a lifetime of patients non-stop, 
because once stalled, HIV in the patient's 
body will soon increase in number (Darcis 
et al., 2017). Though the drug can also 
cause side effects that some patients can 
not tolerate, causing patients to be dis-
obedient in taking drugs (Eckard et al., 
2016; Kwarteng et al., 2017; Mattevi and 
Tagliari, 2017). In addition to drug side-
effects, many factors affect patient adheren-
ce to HIV/ AIDS infection in the treatment 
to be identified and given the solution 
(Croome et al., 2017; Iacob et al., 2017; 
Shubber et al., 2016). Non-adherence to 
antiretroviral treatment in addition to 
increasing the number of HIV in the 
patient's body (worsening the clinical 
course) will also increase HIV resistance to 
antiretroviral drugs (Garbelli et al., 2017; 
Piana et al., 2017). HIV resistance to 
antiretroviral drugs alone has the potential 
to inhibit the planned elimination of AIDS 
as a global health problem by 2030 (Clutter 
et al., 2016). 
Surakarta City is one of the Central 
Java Province cities which has recorded the 
number of HIV/ AIDS infected patients as 
much as 2,428 people until March 2017 
(Ministry of Health, 2017). A number of 
HIV/ AIDS infection patients performing 
antiretroviral therapy at VCT clinic (Volun-
tary Counseling and Testing) RSUD (Regio-
nal General Hospital) Dr. Moewardi in 
Surakarta in August 2017 were 581 patients 
(source: primary, unpublished). Unfortuna-
tely, there has been no evaluation and data 
related to such adherence in the antiretro-
viral therapy program, especially the deter-
minants of patient compliance. Not only in 
Surakarta, as far as the researchers know 
there has been no publication reporting the 
determinants of adherence to HIV/ AIDS 
infection in Indonesia in taking antiretro-
viral drugs. Therefore, the researcher will 
conduct research activity to know the 
determinant of HIV/ AIDS infection patient 
in VCT RSDM in taking an antiretroviral 
drug with health belief model approach, a 
model used to predict health-related 
behavior (promotion) (Jones et al., 2014). 
 
SUBJECTS AND METHOD 
1. Study design 
This was an analytic observational study 
with a cross-sectional design. The study was 
conducted at Dr. Moewardi Hospital, Sura-
karta, Central Java, from February 2018. 
2. Population and sample 
Population in this study was HIV/AIDS 
patients at Dr. Moewardi Hospital, Sura-
karta, Central Java. A sample of 284 in 
Surakarta was selected by exhaustive 
sampling. 
3. Study variables 
The dependent variable was ARV Adheren-
ce. The independent variables were per-
ceived susceptibility, perceived severity, 
perceived benefits, perceived barriers, cue 
to action, and self-efficacy. 
4. Operational definition of  variables 
ARV adherence was defined as the behavior 
of study subjects obtained through self-
report, calculation of the number of pills, 
exactly the time of visit, the exact dose, 
frequency, and percentage of the total 
amount of prescribed medication. The data 
was collected by questionnaire. Measure-
ment scale was categorical, transformed 
into dichotomous coded as follows, i.e. 0 for 
non adhere and 1 for adhere. 
Perceived susceptibility was defined as 
the perception of the study subject concerns 
the risk of his or her health condition. The 
data was collected by questionnaire. The 
data was collected by questionnaire. Mea-
surement scale was continuous, trans-
formed into dichotomous coded as follows, 
i.e. 0 for low and 1 for high. 
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Perceived severity was defined as a 
perception of the study subject about the 
seriousness of a disease. The data was 
collected by questionnaire. Measurement 
scale was continuous.  
Perceived benefits was defined as the 
study subject's perception that antiretro-
viral therapy is beneficial. The data was 
collected by questionnaire. Measurement 
scale was continuous, transformed into 
dichotomous coded as follows, i.e. 0 for low 
and 1 for high. 
Perceived barriers was defined as the 
perception of the study subject of the per-
ceived obstacles to change behavior. The 
data was collected by questionnaire. Mea-
surement scale was continuous, trans-
formed into dichotomous coded as follows, 
i.e. 0 for high and 1 for low. 
Cue to action was defined as a 
behavior was influenced by a thing that 
becomes a signal for the study subject to 
perform an action or behavior. The data 
was collected by questionnaire. Measure-
ment scale was continuous, transformed 
into dichotomous coded as follows, i.e. 0 for 
low and 1 for high. 
Self-efficacy was defined as a the 
subject's belief in oneself to adhere to 
antiretroviral therapy. The data was 
collected by questionnaire. Measurement 
scale was continuous, transformed into 
dichotomous coded as follows, i.e. 0 for low 
and 1 for high. 
5. Data analysis 
The result of characteristic analysis of study 
subject and univariate analysis in the form 
of categorical/ dichotomy data was descri-
bed in frequency (n) and percent (%). Biva-
riate analysis was performed using Chi-
Square test. Multivariate analysis using 
path analysis with SPSS Stata program, 
through the following steps: 
a. Model specification 
b. Model identification 
c. Model fit 
d. Estimation 
e. Model respecification 
6. Research ethics  
The research ethics clearance was obtained 
from the Research Committe at Dr. Moe-
wardi Hospital. Research ethics included 




1. Characteristics of study subject  
Table 1 showed the characteristics of the 
study subjects. Most of the study subjects 
were age >35 years, male 65.8 %, had 
education ≥senior high school 69.4%, and 
income <UMR 55.3%. 
Table 1. Sample characteristics  




 Low  81 28.5 
 High 203 71.5 
2 Perceived beneft   
 Low  49 17.3 
 High 235 82.7 
3 Perceived barrier   
 Low  129 45.4 
 High 155 54.6 
4 Perceived severity   
 Low  70 24.6 
 High 214 75.4 
5 Self-efficacy   
 Low  35 12.3 
 High 249 87.7 
6 Cues to action   
 Low  18 6.3 
 High 266 93.7 
7 Adherence   
 No adhere 61 21.5 
 Adhere 223 78.5 
 
2. Bivariate analysis 
The bivariate analysis on the Table 2 
showed that perceived susceptibility, per-
ceived severity, perceived benefit, cues to 
action, self-efficacy were positively affected 
on Adherence to antiretroviral therapy. 
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Perceived barrier was negatively affected on Adherence to antiretroviral therapy. 
Table 2. The results of bivariate analysis 
Variable 
Adherence 
OR 95% CI  p No adhere Adhere 
N % N % 
Perceived susceptibility 





High 3 1.5 200 98.5 
Perceived beneft 
Low  33 67.3 16 32.7 15.25 7.45 to 31.19 <0. 001 
High 28 11.9 207 88.1 
Perceived barrier 
Low  5 3.9 124 96.1 0.07 0.03 to 0.19 <0. 001 
High 56 21.5 99 63.9 
Perceived severity 
Low  46 65.7 24 34.3  25.43 12.37 to 
52.26 
<0. 001 
High 15  7.0 199 93.0 
Self-efficacy 
Low  27 77.1 8 22.9 21.34 8.96 to 
50.84 
<0. 001 
High 13.7 13.7 215 86.3 
Cues to action 
Low  17 94.4 1 5.6 85.77 11.13 to 
661.33 
<0. 001 
High 44 16.5 222 83.5 
 
3. Path analysis 
The data were analysis using Stata 13 
program. The observed variables were 6, 
endogenous variables were 3, exogenous 
variables were 6, and parameters were 6. 
Degree of freedom formula, as follows:  
df= (observed variable x (observed varia-
ble+ 1))/2 – (endogenous variable+ 
exogenous variable+ parameter) 
= (6 x (6 + 1))/2 – (3 + 6 + 6)  
= 21-15 = 6 
Degree of freedom was over identified 
and path analysis can be done. Structural 
model with estimation of path analysis 
showed in Figure 1. The results of path 
































Figure 1. Structural model after estimation 
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Table 2. The results of path analysis on adherence to antiretroviral therapy 










Adherence  Self-efficacy 2.10 0.85  3.34 0.001 
 Perceived barrier -2.55    -3.70   -1.41 <0.001      
 Perceived beneft 2.08    1.15  3.00 <0.001      
 Cues to action  3.61 0.86   6.36 0.010 
Indirect Effect 
Self-efficacy  Perceived severity 2.98    2.09      3.87 <0.001      
Perceived benefit  Perceived susceptibility 2.08    1.41   0.76 <0.001      
n observation     = 284     
Log Likelihood  
BIC                     

















These values indicate that path analysis 
model in Figure 1 meets the criteria speci-
fied and expressed in accordance with the 
empirical data. 
1. Factors directly affecting on adherence 
to antiretroviral therapy 
Adherence to antiretroviral therapy in HIV/ 
AIDS patient was directly affected by self-
efficacy, perceived barrier, perceived bene-
fit, and cue to action. 
a. There is a direct effect of self-efficacy on 
adherence to antiretroviral therapy and 
statistically significant. High self-efficacy 
has a logodd scores for medication 
adherence of 2.10 units higher than low 
self-efficacy (b= 2.10; 95% CI = 0.85 to 
3.34; p = 0.001). 
b. There is a direct effect of perceived 
barrier on adherence to antiretroviral 
therapy and statistically significant. High 
perceived barrier have a logodd score of 
medication adherence of 2.55 units 
higher than a low perceived barrier (b=  
-2.55; 95% CI = -3.70 to -1.41; p <0.001). 
c. There is a direct effect of perceived 
benefit on adherence to antiretroviral 
therapy and statistically significant. 
Higher perceived benefits have a loggodd 
score of 1.45 units higher than low 
perceived benefit (b= 2.08; 95% CI = 
1.15 to 3.00; p <0.001). 
d. There is a direct effect cues to action on 
adherence to antiretroviral therapy and 
statistically significant. The high cues to 
action have a logodd score of 3.13 units 
higher than low cues to action (b= 3.61; 
95% CI = 0.86 to 6.36; p = 0.010). 
2. Factors indirectly affecting on adherence 
to antiretroviral therapy 
Adherence to antiretroviral therapy in HIV/ 
AIDS patient was indirectly affected by 
perceived severity and perceived suscepti-
bility. 
a. There is a effect of perceived severity 
effect on adherence to antiretroviral 
therapy through self-efficacy and statis-
tically significant. A high perceived 
severity have a logodd score of 2.98 unit 
self-efficacy higher than a low perceived 
severity (b= 2.98; 95% CI = 2.09 to 3.87; 
p <0.001). 
b. There is a effect of perceived suscepti-
bility on adherence to antiretroviral 
therapy through perceived benefit and 
statistically significant. High perceived 
susceptibility have a logodd score of 2.08 
higher perceived benefit than low 
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perceived susceptibility (b= 2.08; 95% 
CI = 1.41 to 0.76; p <0.001). 
 
CONCLUSION 
1. The Effect of Self-Efficacy on Adhe-
rence to Antiretroviral Therapy 
Among HIV/ AIDS Patients. 
The result of this study indicated that high 
self-efficacy may improve adherence to 
antiretroviral therapy. Self-efficacy is a self-
confidence of an individual's ability to well 
perform a certain action so that he tried to 
show the best thing he could do in order to 
achieve the maximum result (Bandura, 
1977 in Sulaeman, 2016). In the health 
belief model, the high perception of health 
threat will increase the self-efficacy of 
individuals, in this case, individuals being 
able to manage the aspects of his efficacy. If 
individuals do not believe or confident that 
they can carry out behavior change, then 
they cannot do it (Simpson, 2015). Self 
efficacy will give impact to treatment 
disobedience. Patients’ knowledge concern-
ing to antiretroviral therapy needs to be 
supported by HIV/ AIDS patients’ belief of 
being able or capable to undergo antiretro-
viral therapy obediently so that it will not 
drop out. Self-efficacy can be established 
from the surrounding environment. 
2. The Effect of Perceived Barrier on 
Adherence to Antiretroviral Thera-
py Among HIV/ AIDS Patients 
The result of this study indicated that high 
perceived barrier may decrease adherence 
to antiretroviral therapy. Based on Health 
Belief Model concept individuals have 
perception concerning the experienced 
barriers that it may influence individuals to 
not change their behavior (Burke, 2015). 
Perceived barrier refers to an individual's 
assessment of the perceived barriers to 
behavior change (Janz and Backer 1984 in 
Sulaeman, 2016). Barriers may reduce 
adherence to antiretroviral therapy. In 
broad line the barriers are financial and 
social barrier. Further, when patient’s belief 
toward barriers or obstacles is reduced or 
disappears then the adherence will be 
increasing. Geographic location also influ-
ence patients’ adherence to antiretroviral 
therapy. The road condition makes it diffi-
cult to go to healthcare facilities or because 
the distance is too far makes HIV/ AIDS 
patients are reluctant to have medical exa-
mination in reliable health care facilities. 
3. The Effect of Perceived Benefit on 
Adherence to Antiretroviral Thera-
py Among HIV/ AIDS Patients 
The result of this study indicated that high 
perceived benefit may improve adherence 
to antiretroviral therapy. Perceived benefit 
refers to the individual assessment of 
efficacy to reduce the risk of disease 
(Resenstock 1974 in Sulaeman, 2016). In 
accordance with Health Belief Model an 
individual has a perception on the benefit 
to be experienced if conducting behavior 
change (Burke, 2015). Direct association 
between perceived benefit and adherence to 
antiretroviral therapy was positive and 
significant. Patients who believe that the 
undergone treatment will give positive 
impact for themselves will be more obe-
dient toward the treatment. In addition, 
someone with high perception toward the 
benefit of antiretroviral therapy will reduce 
any obstacles or barriers they experience. 
Perceived benefit may get improved by 
making excellent communication between 
health personnel and HIV/ AIDS patients. 
It is expected that with good commu-
nication, health personnel may give the 
appropriate education about the benefits 
and importance of regular treatment.  
4. The Effect of Cues to Action on 
Adherence to Antiretroviral Thera-
py Among HIV/ AIDS Patients 
The result of this study indicated that high 
cues for action can improve adherence to 
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antiretroviral therapy. Cues to Action is a 
part of Health Belief Model which is 
anything that encourage decision in 
changing behavior (Horne et al., 2013). 
Good knowledge concerning HIV/ AIDS 
needs to be accompanied by the support 
from closest people. HIV/ AIDS patients 
who live alone and far from their family or 
neighbors will be more likely to stop 
antiretroviral therapy before its time. 
5. The Effect of Perceived Severity on 
Adherence to Antiretroviral Thera-
py Among HIV/ AIDS Patients 
through Self-Efficacy 
The result of this study indicated that high 
perceived severity can increase the 
likelihood of high self-efficacy. Perceived 
severity were a form of assessment of the 
severity of health problems and its potential 
consequences (Janz et al., 1984; Glanz cit 
Sulaeman, 2016). Health Belief Model 
elaborates perceived severity within an 
individual and may influence individual in 
taking action (Simpson, 2015). Individual 
action to conduct treatment and prevention 
for a disease will be encouraged by the 
severity of the disease. The bigger the risk 
of the disease the more likely the individual 
feel threatened. The threat encourages 
individual action to conduct prevention and 
treatment for the disease. 
6. The Effect of Perceived Suscepti-
bility on Adherence to Antiretro-
viral Therapy Among HIV/ AIDS 
Patients through Perceived Benefit 
The result of this study indicated that High 
perceived susceptibility may increase the 
likelihood of high perceived susceptibility. 
Rosenstock et al., (1988) stated that Health 
Belief Model is one of the oldest model that 
discuss the preparation to conduct health 
behavior based on several individual beliefs 
and perception. The study result was in 
accordance with the previous finding that 
mentioned individual belief role in HBM 
influenced individual decision in increasing 
health behaviors, one of them was 
adherence to antiretroviral therapy. 
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